People living with type 2 diabetes and hypertension present different barriers and facilitating factors for disease self-management, in part based on their readiness-to-change and also due to the broader context in which they live.
Calculating statins' social value reveals that consumers captured 76 percent of the total social value of the survival gains, with even greater consumer benefits expected in the future as prescribing rates rise and statin costs decrease.
Hypertensive patients who received a one-time $15 payment to see a doctor and were provided educational materials were more likely to schedule a visit, and pre-hypertensive patients saw a significant and sustained reduction in their blood pressure. However, the financial incentive had no effect on reducing racial or ethnic gaps in hypertension.
Describes a study showing that increasing copayments for prescription drugs causes patients newly diagnosed with hypertension, high cholesterol, and diabetes to delay starting treatment, which in turn increases their risk for heart attack and stroke.
Reducing Americans' average intake of sodium to the amount recommended by health officials could save the nation as much as $18 billion annually in avoided health care costs and improve the quality of life for millions of people.